TaxorestТаксорест
A peptide mixture from the bronchial lining of young cattle or pigs, studied in a Russian respiratory report.
What the studies found
Comparison in people · 2011
Taxorest: clinical report on a tissue-derived preparation
- Forced expiratory vital capacity
- 3,940.5 ± 123.6 mL with Taxorest versus 3,225.6 ± 148.2 mL with conventional care. Shared baseline 2,767.8 ± 134.7 mL.
- Vital capacity
- 4,220.7 ± 243.1 mL with Taxorest versus 3,876.5 ± 215.4 mL with conventional care. Shared baseline 3,654.1 ± 231.9 mL.
- Total lung capacity
- 5,246.1 ± 223.6 versus 5,075.4 ± 211.6 mL. The table gives no significance mark for total lung capacity.
Forced expiratory vital capacity was 3,940.5 mL with adjunctive Taxorest and 3,225.6 mL with conventional care. Significance was marked against the shared baseline.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 52 smokers with bronchitis: 31 treated, 21 controls.
Design 52 smokers with chronic bronchitis in remission, 31 receiving adjunctive Taxorest and 21 conventional therapy alone. The studied oral schedule was one 10 mg capsule with meals twice daily (20 mg/day) for 30 days.
Important limitations
- Allocation and blinding are not established. Within-group improvement cannot establish superiority or protection against smoking-related disease. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
- The table marks changes against the shared baseline. It gives no between-group statistical test.
Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date · Institute report — commercial reproduction
About Taxorest
Identity / background source ↗
Research background
Taxorest is a respiratory tissue peptide preparation. A 52-person Medical Center report measured pulmonary function in smokers with bronchitis.
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
52 smokers with bronchitis: 31 treated, 21 controls.
Study methods
Small comparative institute report; allocation, blinding and outcome interpretation require caution
Independent replication
Independent replication not established in this collection
Source access
Report reproduction linked; source language and review scope shown per record
Safety evidence
Short-term reports do not establish long-term safety or equivalence to current products
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2011
Taxorest: clinical report on a tissue-derived preparation
Forced expiratory vital capacity was 3,940.5 mL with adjunctive Taxorest and 3,225.6 mL with conventional care. Significance was marked against the shared baseline.
Forced expiratory vital capacity · 3,940.5 ± 123.6 mL with Taxorest versus 3,225.6 ± 148.2 mL with conventional care. Shared baseline 2,767.8 ± 134.7 mL.
Study notes and original source
Taxorest: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
Forced expiratory vital capacity was 3,940.5 mL with adjunctive Taxorest and 3,225.6 mL with conventional care. Significance was marked against the shared baseline.
Results and tables
Reported findings and study design
52 smokers with chronic bronchitis in remission, 31 receiving adjunctive Taxorest and 21 conventional therapy alone. The studied oral schedule was one 10 mg capsule with meals twice daily (20 mg/day) for 30 days.
Population or model 52 smokers with bronchitis: 31 treated, 21 controls.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Forced expiratory vital capacity | 3,940.5 ± 123.6 mL with Taxorest versus 3,225.6 ± 148.2 mL with conventional care. Shared baseline 2,767.8 ± 134.7 mL. | |
| Vital capacity | 4,220.7 ± 243.1 mL with Taxorest versus 3,876.5 ± 215.4 mL with conventional care. Shared baseline 3,654.1 ± 231.9 mL. | |
| Total lung capacity | 5,246.1 ± 223.6 versus 5,075.4 ± 211.6 mL. The table gives no significance mark for total lung capacity. |
The table marks changes against the shared baseline. It gives no between-group statistical test.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 52 smokers with bronchitis: 31 treated, 21 controls.
- Source reviewed
- Russian Medical Center report, PDF pages 80–81, methods and spirometry table.
Study limitations
- Allocation and blinding are not established. Within-group improvement cannot establish superiority or protection against smoking-related disease.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗